United Therapeutics: Q3 Earnings Snapshot – WTOP News

United Therapeutics (UTHR) Q3 2026 Earnings Call Transcript

Tyvaso DPI growth lifted revenue while R&D spending weighed on profit.

BTIG Research Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

BTIG Research increased their price target on United Therapeutics from $728.00 to $768.00 and gave the stock a "buy" rating in a research note on Wednesday.

United Therapeutics: Q3 Earnings Snapshot – WTOP News

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported third-quarter profit of $258.6 million. The Silver Spring, Maryland-based company said it had profit of $5.71 per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings...

United Therapeutics: Q3 Earnings Snapshot

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported third-quarter profit of $258.6 million.

Recent Analysts’ Ratings Updates for United Therapeutics (UTHR)

Several analysts have recently updated their ratings and price targets for United Therapeutics (NASDAQ: UTHR): 10/28/2026 – United Therapeutics had its price target lowered by JPMorgan Chase & Co. from $710.00 to $695.00. They now have an “overweight” rating on the stock. 10/26/2026 – United Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They […]

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $596.22, for a total transaction of $5,664,090.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $193,439,405.46. The trade was a 2.84% decrease in…